Off-target effects of thrombolytic drugs apolipoprotein A-I proteolysis by alteplase and tenecteplase》.pdfVIP

Biochemical Pharmacology 85 (2013) 525–530 Contents lists available at SciVerse ScienceDirect Biochemical Pharmacology jo u rn al h om epag e: ww w.els evier.c o m/lo cat e/bio c hem p har m Off-target effects of thrombolytic drugs: apolipoprotein A-I proteolysis by alteplase and tenecteplase Monica Gomaraschi a, Alice Ossoli a, Cecilia Vitali a, Silvia Pozzi a, Laura Vitali Serdoz b, Cristina Pitzorno b, Gianfranco Sinagra b, Guido Franceschini a, Laura Calabresi a,* a ` Centro Enrica Grossi Paoletti, Dipartimento di Scienze Farmacologiche e Biomolecolari, Universita degli Studi di Milano, Milano, Italy b Cardiovascular Department, Ospedali Riuniti and University of Trieste, Trieste, Italy A R T I C L E I N F O A B S T R A C T Article history: The administration of thrombolytic drugs is of proven benefit in a variety of clinical conditions requiring Received 18 September 2012 acute revascularization, including acute myocardial infarction (AMI), ischemic stroke, pulmonary Accepted 26 November 2012 embolism, and venous thrombosis. Generated plasmin can degrade non-target proteins, including Available online 5 December 2012 apolipoprotein A-I (apoA-I), the major protein constituent of high-density lipoproteins (HDL). Aim of the present study was to compare the extent of apoA-I proteolytic degradation in AMI patients treated with Keywords: two thrombolytic drugs,